PFE logo
Pfizer Inc.
PFE
25.06 (-2.67%) 0.67
Health Care
Pharmaceuticals
Pfizer Inc. discovers develops manufactures markets distributes and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas including cardiovascular and migraine under the Eliquis Nurtec ODT/Vydura Zavzpret and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family Abrysvo Nimenrix FSME/IMMUN-TicoVac and Trumenba brands; and COVID-19 prevention and treatment and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz Enbrel Inflectra Litfulo Velsipity and Cibinqo brands; amyloidosis hemophilia endocrine diseases and sickle cell disease under the Vyndaqel family Oxbryta BeneFIX Somavert Ngenla and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon Medrol Zavicefta Zithromax Octagam and Panzyga brands; and biologics small molecules immunotherapies and biosimilars under the Ibrance Xtandi Padcev Adcetris Inlyta Lorbrena Bosulif Tukysa Braftovi Mektovi Orgovyx Elrexfio Tivdak and Talzenna brands. In addition the company involved in the contract manufacturing business. It serves wholesalers retailers hospitals clinics government agencies pharmacies individual provider offices retail pharmacies and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York New York.

Quality Checklist 3/8

Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
5Y Shares Out Change < 0%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $142.48(B)
EV: $189.73(B)
Total Equity: $93.10(B)
Earnings date: Feb-03-2026
P/E: 14.49
Forward P/E: 7.98
P/FCF: 13.77
P/S: 2.27
P/B: 1.54
EPS: $1.7
EPS (fwd): $3.1
FCF/share: $1.8
Revenue/share: $11.1
Book value/share: $16.3
ROIC: 6.3%
ROA: 4.6%
ROE: 10.6%
Debt/Equity: 0.67
Current Ratio: 1.30
Gross margin: 74.8%
Operating margin: 24.6%
Net margin: 15.7%
Dividend/share: $1.7
Div. yield: 6.78%

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$62.78(B)
Gross profit$46.97(B)
EBITDA$24.46(B)
Net income$9.83(B)
Gross margin74.8%
Operating margin24.6%
Net margin15.7%
Shares outstanding5.69(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$208.73(B)
Current assets$46.92(B)
Total liabilities$115.64(B)
Current liabilities$36.60(B)
Cash & Short-term inv.$14.99(B)
Long-term debt$57.63(B)
Total intangibles$120.42(B)
PP&E$18.88(B)

Cash flow (TTM)

CFOCFICFF
FCF$10.38(B)
CapEx$-2.70(B)
Dividends paid$-9.71(B)
Stock issued$0
Stock repurchased$0
Stock-based comp.$767.00(M)
Debt issued$4.42(B)
Debt repaid$-10.30(B)

Per share data (TTM)

Price: $25.1
Revenue: $11.1 (2.3x | 44.1%) Gross profit: $8.26 (3.0x | 33.0%) Earnings: $1.73 (14.5x | 6.9%)
FCF: $1.82 (13.8x | 7.3%) Stock-based Comp.: $0.13 (185.8x | 0.5%) CapEx.: $0.48 (52.8x | 1.9%) Dividend: $1.70 (14.7x | 6.8%)
Total Assets: $36.7 (0.7x | 146.5%) Total Liabilities: $20.3 (1.2x | 81.2%) Book Value: $16.3 (1.5x | 65.1%) Cash & ST inv.: $2.64 (9.5x | 10.5%) Debt: $10.1 (2.5x | 40.4%)
Earnings FY+1: $3.14 (8.0x | 12.5%) Earnings FY+2: $3.13 (8.0x | 12.5%) Earnings FY+3: $3.04 (8.2x | 12.1%) Earnings FY+4: $2.72 (9.2x | 10.9%) Earnings FY+5: $2.41 (10.4x | 9.6%)
FCF FY+1: $2.93 (8.6x | 11.7%) FCF FY+2: $3.42 (7.3x | 13.6%) FCF FY+3: $3.29 (7.6x | 13.1%) FCF FY+4: $3.08 (8.1x | 12.3%) FCF FY+5: $2.88 (8.7x | 11.5%)

Summary